The WLA Prize is an international science award established at the forum in 2021. It aims to recognize exceptional ...

Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

We asked five academics with expertise in sexual health, nutrition, psychiatry, bioethics and drug policy. Here’s what they said.

Patients with PD-L1-positive metastatic triple-negative breast cancer reported improved emotional function and pain with sacituzumab govitecan plus pembrolizumab compared with chemotherapy plus ...

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic ...

After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state ...